Kornimate/medical-research-clean huggingface dataset:
a rct to compare ohrqol outcome for slb and cb

Conditions: Malocclusion

Summary: the objective of this prospective study is to compare these two treatments (conventional brackets v.s. self-ligating brackets) in malocclusion to determine which treatment will provide the better oral health related quality of life (ohrqol) outcomes for patients during the initial orthodontic treatment compared with pretreatment.


Eligibility criteria:
inclusion criteria: * malocclusion patients * age between 12 to 40 years * suitable for orthodontic treatment using either self-ligating brackets or conventional brackets. exclusion criteria: * any surgery performed in the previous days, * previous temporomandibular joint arthrotomies, * fewer than 20 teeth total or fewer than 10 teeth in each arch, * unstable residence or travel restrictions, * periodontal disease judged to be severe by the surgeon, * pregnancy, * previous mandibular surgery, and * inability to follow instructions or the study protocol.

Keywords: oral health-related quality of life (ohrqol) self-ligating brackets (slb) conventional brackets (cb) oral health impact profile-14 (ohip-14) short form-36 (sf-36)
objective measurements of prolonged effects of restasis on dry eye disease

Conditions: Treatment of Dry Eye Disease

Summary: we propose to investigate the response to restasis, over a prolonged period of time in heavy computer users with dry eye disease.


Eligibility criteria:
inclusion criteria: * using computers more than three hours per day * having dry eye symptoms based on results on the osdi scores of 15 or greater on the osdi will be considered to have the disorder * an abnormal confocal image of 5 or greater. exclusion criteria: * all corneal disorders except for tear disorders.
delivery of protocolised emergency surgical care during covid-19 pandemic

Conditions: COVID-19; Emergency Surgery

Summary: emergency general surgical care during the covid-19 pandemic presents a unique set of considerations and challenges. patients presenting with acute surgical conditions and concomitant covid-19 infection have higher risk of mortality and morbidity. the investigators present their experience with covid-19 positive patients presenting with acute surgical conditions and reviewed the implementation of a protocolized pathway to mitigate the impact of covid-19 infection.

all covid-19 positive patients who presented to the acute general surgical service over a 2-month period were identified. patient data including demographics, surgical diagnosis, mortality, morbidity and hospital length of stay was collected. based on the investigators' early experience from the first patient, the investigators designed a protocolized institutional pathway which incorporated the risk of covid-19 infection and urgency of operation.

Eligibility criteria:
inclusion criteria: * all patients with emergency surgical conditions and tested positive for covid-19 infection exclusion criteria: * nil
effect of acupressure in the management of postmenopausal constipation

Conditions: Constipation

Summary: this study was conducted to investigate the effect of acupressure in the management of constipation in postmenopausal women.

constipation is prevalent in menopause, affecting 4-29% of women globally, and can lead to serious complications like hemorrhoids, anal fissures, and colorectal cancer. while laxatives can help, long-term use may cause dependency and side effects. alternative therapies are needed. deep breathing, particularly diaphragmatic breathing, may improve constipation by activating the parasympathetic system and promoting relaxation. acupressure has also shown potential in managing constipation by stimulating intestinal activity, improving blood circulation, and regulating qi flow. despite existing studies on acupressure and constipation, no research has specifically examined its effect on postmenopausal women. this study aims to investigate acupressure's impact on functional constipation in this population, offering potential insights for non-pharmacological management.

Eligibility criteria:
inclusion criteria: 1. sixty postmenopausal women who were clinically diagnosed as having functional constipation after menopause (at least one year after the stoppage of the last menstrual cycle) 2. their ages ranged from 50 to 60 years old. 3. their body mass index didn't exceed 30 kg/m2. 4. all of them should have at least two criteria of rome iii diagnostic criteria of constipation. 5. they should stop laxatives intake during the treatment program. exclusion criteria: 1. irritable bowel syndrome or anal fissures. 2. genital organ prolapse as rectocele. 3. any neurological diseases, spinal diseases or spinal deformities. 4. history of bowel surgery. 5. congenital anorectal malformation, stoma in situ. 6. diabetes mellitus and sever distal venous insufficiency. 7. skin eruption at the site of stimulation. 8. implanted pacemaker or defibrillator. 9. metalic implant in lower limb. 10. recent surgery at the lower limb. 11. peripheral neuropathy and neurological disorders. 12. psychological distress.
enhanced versus standard blood pressure lowering on intracranial aneurysm rupture or growth china antihypertensive trial for intracranial aneurysm (chatia-1)

Conditions: Unruptured Intracranial Aneurysm

Summary: the goal of this randomized controlled trial is to evaluate the benefits and safety of controlled hypotension in chinese patients with unruptured intracranial aneurysms(uia). the main questions it aims to answer are: * to provide high-level evidence of the benefits and safety of controlled hypotension in patients with uia. * to provide evidence-based medical evidence for blood pressure control of patients with uia in neurosurgery, and promote the progress of accurate individual management of patients. in this study, the main intervention is enhanced blood pressure lowering in patients with uia. all patients will be randomly assigned to either the standard blood pressure lowering (sbpl) group or the enhanced blood pressure lowering (ebpl) group.


Eligibility criteria:
inclusion criteria: 1. age 18-75; 2. chinese ethnicity; 3. history of hypertension (as diagnosed per standard of care) 4. under active treatment for hypertension: in the past one month (before enrollment), the blood pressure was controlled at the borderline statue (systolic pressure as 120-140 mmhg, diastolic pressure as 70-80 mmhg) ; 5. good medication adherence (morisky medication adherence scale ≥6) 6. single unruptured intracranial aneurysm (uia) identified by computational tomography angiography, magnetic resonance angiography or digital subtraction angiography within 1 year, and receiving conservative treatment 7. maximal size of uia at largest dimension \< 7mm; 8. uia is regular (no bleb(s) or secondary aneurysm(s) protruding from the uia fundus or bi-/multi-lobular uia fundus). the regular shape and aneurysm size will be evaluated by the central core lab (including a senior neuroradiologist and two neurosurgeons) based on the three-dimensional angiographic imaging; exclusion criteria: 1. neurological symptom related to uia, such as sentinel headache, oculomotor paralysis and so on; 2. additional active intracranial disease including vasculopathy, arteriovenous malformation/fistula, cancer, traumatic brain injury etc; 3. fusiform, dissecting, blister, traumatic, mycotic/bacterial, myxomatous, and tumor-associated uias are excluded; 4. history of polycystic kidney disease, rheumatic disease or autoimmune disease; 5. family history of intracranial aneurysm (defined when two direct relatives of patients within three generations have intracranial aneurysms or aneurysmal subarachnoid hemorrhage);
prevention of pressure ulcer by lateral tilt bed in neurocritical care

Conditions: Pressure Ulcer

Summary: patient positioning is an essential part of a preventive strategy for neurocritical care patients. the aim of the study will be to determine whether the positioning of the bed is the same or better compared to the positioning of the patient's bed in the presence of pressure ulcer.

in the monocentric, intervention, prospective, randomized study, we will investigate incidence of pressure ulcer in 300 adult consecutive patients admitted to our neurointensive care unit (nicu). all patients will suffer from acute primary brain disease and will be unconscious with artificial pulmonary ventilation.

Eligibility criteria:
inclusion criteria: * primary brain disease * hospitalization in jip neurocenter * age\> 18 years * unconsciousness * artificial pulmonary ventilation exclusion criteria: * intracranial hypertension * decubitus on the skin upon admission

Keywords: pressure ulcer neurocritical care acute brain disease unconsciousness preventive strategy
almonertinib plus metronomic oral vinorelbine

Conditions: EGFR; NSCLC; Third-generation TKI

Summary: to evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

this study is a clinical observation study. the patients who comfirm the criteria will be treated with almonertinib plus metronomic oral vinorelbine. the patients will be followed up until the tumor progressed, and the efficacy (pfs, orr, dcr) of tumor therapy were evaluated. drug administration regimen: ametinib 110mg once a day; oral vinorelbine 40mg three times a week for three weeks and q28d for one course.

Eligibility criteria:
inclusion criteria: * non-small cell lung cancer diagnosed by histopathology or cytology; * previous molecular pathology was egfr sensitive mutation; * stage iv; * ecog score 0-2; * prior to receiving the third generation of egfr-tki targeted therapy, and tki targeted therapy showed limited progress; * according to recist1.1 standards, there are measurable or evaluable lesions * the patient has fully understood this study and voluntarily signed a written informed consent form; * the estimated survival time is more than 3 months. exclusion criteria: * histological or cytological confirmation of small cell lung cancer or squamous cell carcinoma at the first diagnosis; * the progression of the third generation egfr-tki suggests histological transformation.
a phase ii study to explore the safety and activity of dersalazine in patients with mild to moderate ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of the study is to obtain a first clinical assessment of the safety of dersalazine sodium in ulcerative colitis patients with mild to moderate disease.


Eligibility criteria:
inclusion criteria: * age 18 to 65 inclusive * male, non-child-bearing female or fertile female with appropriate contraception. * mild to moderate confirmed active ulcerative colitis * able and willing to give informed consent exclusion criteria: * colitis of other cause * pregnancy, inadequate contraception for fertile female patients * liver or kidney disease, unstable cardiovascular disease, coagulation disorder. * other significant medical condition that preclude participation at investigator criteria * allergy or hypersensitivity to salicylates * previous or concomitant treatment for ulcerative colitis interfering with safety or activity assessments
oral gel containing phtalox® as an adjuvant in the treatment of periodontal disease

Conditions: Periodontitis

Summary: periodontitis, a chronic inflammatory condition of the periodontal tissues, impacts not only the patient's oral and systemic health but also has significant social and economic implications. while mechanical treatment effectively removes calculus and dental biofilm, it may fail to eliminate pathogenic bacteria in soft tissues and in areas inaccessible to periodontal instruments, such as furcation regions, root concavities, interproximal areas, and deep periodontal pockets. consequently, adjuvant therapies with antimicrobial and anti-inflammatory potential represent a valuable strategy for periodontitis treatment. in this context, an oral gel containing a phthalocyanine derivative, known for its antimicrobial and anti-inflammatory properties, offers a promising enhancement to conventional periodontal treatment. this randomized controlled clinical trial aimed to evaluate the effect of the topical application of an oral gel formulation containing iron tetracarboxyphthalocyanine (phtalox®) in the non-surgical periodontal treatment. patients with periodontitis underwent a standard periodontal treatment protocol (scaling and root planing), followed by adjuvant therapy according to the assigned groups: vehicle group: toothbrushing with dental gel and local application of the phtalox® oral gel vehicle. chlorhexidine group: toothbrushing with dental gel and local application of 0.12% chlorhexidine oral gel. phtalox® group: toothbrushing with dental gel and local application of 1% phtalox® oral gel. clinical evaluations (plaque index, probing depth, bleeding on probing, clinical attachment level, and mobility test) were performed at baseline (day 0) and post-treatment (day 45).


Eligibility criteria:
inclusion criteria: * patients diagnosed with periodontitis stages ii to iv (moderate to severe) grades a-c, with at least two non-adjacent interproximal sites showing probing depth (pd) ≥5 mm, clinical attachment level (cal) ≥3 mm, and bleeding on probing exclusion criteria: * medical conditions requiring antibiotic prophylaxis or that could influence the response to treatment. * history of periodontal treatment within the last 6 months. * use of medications affecting periodontal tissues within the last 3 months (antibiotics, anti-inflammatory drugs, anticonvulsants, immunosuppressants, or calcium channel blockers). * smokers or former smokers within the last 12 months. * pregnancy. * extensive prosthetic rehabilitation. * undergoing orthodontic treatment. * individuals with blood dyscrasias. * alcoholism. * use of illicit drugs.
heart evaluation of acute ischemic stroke with reperfusion therapy

Conditions: Acute Ischemic Stroke

Summary: heart evaluation of acute ischemic stroke with reperfusion therapy (heart) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy. this registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.

there is growing evidence pointing to close interactions between acute ischemic stroke (ais) and heart diseases. heart diseases may lead to ais (heart-to-brain interactions), with many cardiac conditions have been proposed as potential sources of cerebral embolism, and studies have also shown that ais can induce cardiac injury (brain-to-heart interactions), namely stroke-heart syndrome. in addition, due to the commonly shared risk factors, ais patients had a significantly higher frequency of coexisting prior known or unknown coronary heart disease (brain-and-heart interactions). these heart problems not only add complexity to the etiological diagnosis but also account for a great proportionate mortality in ais patients with reperfusion therapy, which is the most effective treatment method for ais. the interconnected and coexisting properties of ais and heart diseases requires a comprehensive scheme to evaluate, prevent, and treat patients. heart evaluation of acute ischemic stroke with reperfusion therapy (heart) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy. this registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies. the clinical, laboratory and imaging information will be collected at the baseline. during an estimated 3-year follow-up, the diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.

Eligibility criteria:
inclusion criteria: 1. written informed consent by patient 2. age ≥ 18 years 3. acute ischemic stroke (with matching brain lesion on mr imaging) 4. enrolment within 24 h after onset of stroke-related symptoms. exclusion criteria: 1. pregnancy and / or breast-feeding. 2. participation in an interventional study. 3. patients refuse to participate in the research.

Keywords: acute ischemic stroke heart reperfusion therapy
effect of valproate on propofol

Conditions: Mental Retardation

Summary: the aim of this study is to evaluate the effect of valproate on the required dose of propofol for sedation in patients with mental retardation.

the intravenous sedation with propofol is very useful for patients with mental retardation and challenging behavior. however, it is very difficult to titrate the dose of propofol for maintaining the adequate sedation depth because of the difficulty of verbal communication with them. most of them have a epilepsy and take antiepileptic drugs. antiepileptic drugs are thought to influence on the effect of anesthetics. valproate is reported to inhibit the metabolism of propofol. therefore, we divide the patients into two groups : patients receiving valproate (valproate group), patients receiving no antiepileptic drugs (control group), and compare the required dose of propofol and the recovery time.

Eligibility criteria:
inclusion criteria: 1. patients aged 16 or over 2. american society of anesthesiologists (asa) physical status 1 or 2 3. the treatment of dental caries, endodontics, periodontics and prosthesis were planed 4. participants had moderate or severe mental retardation, and were not completely cooperated with dental treatment exclusion criteria: 1. patients could communicate and cooperate with dental treatment, but used dental sedation for decrease of the anxiety and the fear about dental treatment or another reasons 2. patients needed premedication and inhalational anesthetics 3. patients had uncontrolled or sever medical condition

Keywords: intravenous sedation dental treatment mental retardation antiepileptic drug valproate propofol
surgical treatment of concurrent cataract and primary pterygium

Conditions: Pterygium; Cataract; Lenses, Intraocular

Summary: pterygium is known to induce with-the-rule astigmatism. the corneal curvature along the long axis of the pterygium body is flattened. the excision of pterygium will result in steepening of the cornea and reduction of astigmatism. therefore, the effect of pterygium excision on intraocular lens (iol) power calculation has been examined in our previous study. the study confirmed that pterygium can cause alteration of iol power. the determination of iol power for cataract surgery is usually calculated from iol formula called srk ii formula. iol power = a - (2.5 x al)-(0.9 x k). variable a denotes the a-constant of the intraocular lens which is dependent on the iol material and refractive index. other variables for input include axial length (al) and keratometry (k). a larger k reading will result in a lower estimated iol power and vice versa. previous studies have documented simultaneous cataract and pterygium operation resulted in reasonable visual outcome without adjustment of iol power. with the presence of a pterygium, the cornea is flattened and lead to a reduction of k value and over-estimation of calculated iol power. this randomized controlled trial is designed to compare the refractive outcomes of sequential and simultaneous pterygium and cataract operation. pterygium excision should be done with various adjuvant therapies to minimize recurrence. our previous studies reliably demonstrated limbal conjunctival graft and mitomycin c were effective methods to achieve low pterygium recurrence. we use limbal conjunctival autograft as the adjuvant therapy in the current study because this method is safer to be performed either alone or in combination with phacoemulsification. we avoid using mitomycin c as the adjuvant therapy in order to minimize the possibility of intraocular toxicity due to seepage.


Eligibility criteria:
inclusion criteria: * \>18 years old * primary pterygium \> 2mm across corneal limbus \[measurement made from the imaginary line of surgical limbus to the most advance edge of the visible pterygium tissue\] concurrent visually significant cataract ( bcva \< 20/70 ) * informed consent for both pterygium and cataract surgery exclusion criteria: * temporal pterygium * double headed pterygium * previous ocular surgery in which conjunctival-limbal graft is not feasible * pterygium covering visual axis that preclude keratometric assessment * history of scleritis or autoimmune diseases

Keywords: pterygium cataract intraocular lens power calculation accuracy
hematopoietic stem cell support in patients with severe crohn's disease

Conditions: CROHN'S DISEASE

Summary: this disease is believed to be caused by immune cells (called lymphocytes) attacking tissue. risk of death is highest in people with active acute disease. in addition, progressive crohn's disease leads to further loss of bowel function, which may eventually result in the need for artificial nutritional support (parenteral nutrition). this study involves high dose chemotherapy followed by return (infusion) of blood stem cells. stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. the high dose chemotherapy consists of cyclophosphamide and anti lymphocyte antibody (a protein that depletes cells that cause damage to the body). the purpose of the intense chemotherapy is to destroy the immune system completely. the purpose of the stem cell infusion is to restore the body's blood production, which will be severely impaired by the high dose chemotherapy and anti lymphocyte antibody.


Eligibility criteria:
inclusion criteria: 1. less than physiologic age 60 at time of pretransplant evaluation 2. an established clinical diagnosis of severe cd that has failed therapy with prednisone, azathioprine, 5 asa products and metronidazole, and has failed an anti-tnf alpha inhibitor. failure is defined as a cdai (appendix a) 250-400 or a craig severity score that is \> 17 (appendix d) 3. pre-study peripheral blood counts must include a platelet count greater than 100,000/ul and an absolute neutrophil count greater than 1500/ul. 4. stem cell harvest greater than 1.4 x 106 cd34 cells/kg after cd34+ selection (to continue to transplant) 5. ability to give informed consent exclusion criteria 1. hiv positive 2. history of coronary artery disease, or congestive heart failure 3. uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy 4. prior history of malignancy except localized basal cell or squamous skin cancer. other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage i breast cancer will be considered on an individual basis 5. positive pregnancy test, lactation, inability or unwillingness to pursue effective means of birth control, failure to accept or comprehend irreversible sterility as a side effect of therapy 6. psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible 7. fev i/fvc \< 50% of predicted, dlco \< 50% of predicted 8. resting lvef \< 40% 9. bilirubin \> 2.0 mg/dl, transferase (ast) \> 2x upper limit of normal, unless the abnormalities are secondary to crohn's disease 10. serum creatinine \> 2.0 mg/dl 11. platelet count less than 100,000/ul, anc less than 1500/ul 12. patients presenting with intestinal perforation or toxic megacolon, or a suppurative problem that will require urgent surgery. in addition, the patient may not have any active infection. the presence of intestinal stomas does not exclude the patient from study.